Our mission at Prescribe Right is to offer budget-friendly products that provide the information you need to proactively plan for budget-busting drugs. To commemorate our 100th COVID-19 update we are offering access to the knowledgebase for 100 hours or 100 days whichever comes first, for only $100. This offer expires at 11:59 pm on Friday, September 24, 2021.
Booster Vaccine Doses
ACIP recommended that COVID-19 vaccines can be coadministered with other vaccines, including influenza vaccines in their 2021–22 Influenza Season update.
Pfizer and BioNTech announced that in a 2,268 patient, Phase II/III trial (NCT04816643), two 10 mcg doses of their COVID-19 vaccine given 21 days apart, to children 5 to 11 years, produced antibody titers comparable to the levels seen with two 30 mcg adult doses in adolescents and young adults age 16 to 25 years. Data for children 2 to 5 years of age and children 6 months to 2 years of age is forecast to be available in the fourth quarter.
In a review of data from 1,736,832 patients from an Israeli managed care database, found the Pfizer/BioNTech COVID-19 vaccine increases the risk for lymphadenopathy, herpes zoster infection and appendicitis, while COVID-19 increases the risk for arrhythmia, acute kidney injury, pulmonary embolism, deep-vein thrombosis, myocardial infarction, pericarditis, and intracranial hemorrhage. While the vaccine increased the risk for myocarditis (2.7 events per 100,000 persons) the risk was over four times higher with COVID-19 (11.0 events per 100,000 persons).
The FDA expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab (Lilly) to include post-exposure prophylaxis in high-risk individuals 12 years of age and older who have not been fully vaccinated against COVID-19 or are not expected to mount an adequate immune response to complete vaccination and have been exposed COVID-19.
In the 15-day, 857 patient, Phase III, DisCoVeRy trial (NCT04315948), adding remdesivir to standard-of care did not improve clinical status (WHO seven-point ordinal scale) compared to standard-of-care alone in European hospitalized patients with COVID-19 for more than 7 days, who were receiving supplemental oxygen.
Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker